These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8549381)

  • 1. Experimental and clinical studies of sparfloxacin in Mycoplasma pneumoniae infection.
    Kaku M; Ishida K; Kohno S; Koga H; Hara K; Usui T
    Drugs; 1995; 49 Suppl 2():412-3. PubMed ID: 8549381
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro and in vivo activities of sparfloxacin against Mycoplasma pneumoniae.
    Kaku M; Ishida K; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    Antimicrob Agents Chemother; 1994 Apr; 38(4):738-41. PubMed ID: 8031039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae.
    Gohara Y; Arai S; Akashi A; Kuwano K; Tseng CC; Matsubara S; Matumoto M; Furudera T
    Antimicrob Agents Chemother; 1993 Sep; 37(9):1826-30. PubMed ID: 8239590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae.
    Takahata M; Shimakura M; Hori R; Kizawa K; Todo Y; Minami S; Watanabe Y; Narita H
    Antimicrob Agents Chemother; 2001 Jan; 45(1):312-5. PubMed ID: 11120986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of new quinolones on Mycoplasma pneumoniae-infected hamsters.
    Arai S; Gohara Y; Akashi A; Kuwano K; Nishimoto M; Yano T; Oizumi K; Takeda K; Yamaguchi T
    Antimicrob Agents Chemother; 1993 Feb; 37(2):287-92. PubMed ID: 8383942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1996 Apr; 40(4):1048-9. PubMed ID: 8849228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae.
    Ishida K; Kaku M; Irifune K; Mizukane R; Takemura H; Yoshida R; Tanaka H; Usui T; Tomono K; Suyama N
    J Antimicrob Chemother; 1994 Dec; 34(6):875-83. PubMed ID: 7730231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Mycoplasma pneumoniae to several new quinolones, tetracycline, and erythromycin.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1991 Mar; 35(3):587-9. PubMed ID: 1903913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1993 Aug; 37(8):1726-7. PubMed ID: 8215294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Antimicrobial Susceptibilities among
    Oishi T; Takahashi K; Wakabayashi S; Nakamura Y; Ono S; Kono M; Kato A; Saito A; Kondo E; Tanaka Y; Teranishi H; Akaike H; Tanaka T; Miyata I; Ogita S; Ohno N; Nakano T; Ouchi K
    Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of sparfloxacin against Mycobacterium leprae measured by the proportional bactericidal test.
    McDermott-Lancaster RD; Banerjee DK
    Int J Lepr Other Mycobact Dis; 1993 Dec; 61(4):605-8. PubMed ID: 8151193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
    Roblin PM; Montalban G; Hammerschlag MR
    Antimicrob Agents Chemother; 1994 Jun; 38(6):1402-3. PubMed ID: 8092845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of oxytetracycline and erythromycin on Syrian hamsters after intratracheal infection with Mycoplasma pneumoniae.
    Ritter E; Lange A; Rockel C; Ortel J
    J Hyg Epidemiol Microbiol Immunol; 1987; 31(1):83-9. PubMed ID: 3106470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levofloxacin and sparfloxacin: new quinolone antibiotics.
    Martin SJ; Meyer JM; Chuck SK; Jung R; Messick CR; Pendland SL
    Ann Pharmacother; 1998 Mar; 32(3):320-36. PubMed ID: 9533064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro activity of sparfloxacin against mycoplasmas].
    Renaudin H; Bebear C
    Pathol Biol (Paris); 1992 May; 40(5):450-4. PubMed ID: 1323094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of in-vitro activity of new quinolones, macrolides, and minocycline against Mycoplasma pneumoniae.
    Ikejima H; Yamamoto H; Ishida K; Kaku M; Shimada J
    J Infect Chemother; 2000 Sep; 6(3):148-50. PubMed ID: 11810555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bactericidal activity of levofloxacin against Mycoplasma pneumoniae.
    Duffy LB; Crabb DM; Bing X; Waites KB
    J Antimicrob Chemother; 2003 Sep; 52(3):527-8. PubMed ID: 12888583
    [No Abstract]   [Full Text] [Related]  

  • 18. [The use of Maxaquin (lomefloxacin hydrochloride) in the treatment of nonspecific inflammatory diseases and in the prevention of surgical interventions in urology].
    Derevianko II; Lopatkin NA; Khodyreva LA; Kondrat'eva EM
    Urol Nefrol (Mosk); 1998; (5):14-8. PubMed ID: 9820038
    [No Abstract]   [Full Text] [Related]  

  • 19. In vitro activity of sparfloxacin compared with ciprofloxacin and ofloxacin against respiratory tract pathogens.
    Malmborg AS; Ahlén S
    Chemotherapy; 1993; 39(1):32-5. PubMed ID: 8383030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibilities of Mycoplasma hominis and Ureaplasma urealyticum to two new quinolones, sparfloxacin and WIN 57273.
    Kenny GE; Cartwright FD
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1515-6. PubMed ID: 1929320
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.